Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)2 and the larger HDL3 from very low-density lipoprotein (VLDL)
Open Access
- 27 November 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 402 (4), 439-449
- https://doi.org/10.1515/hsz-2020-0288
Abstract
Triglyceride hydrolysis by lipoprotein lipase (LPL), regulated by apolipoproteins C-II (apoC-II) and C-III (apoC-III), is essential for maintaining normal lipid homeostasis. During triglyceride lipolysis, the apoCs are known to be transferred from very low-density lipoprotein (VLDL) to high-density lipoprotein (HDL), but the detailed mechanisms of this transfer remain unclear. In this study, we investigated the extent of the apoC transfers and their distribution in HDL subfractions, HDL2 and HDL3. Each HDL subfraction was incubated with VLDL or biotin-labeled VLDL, and apolipoproteins and lipids in the re-isolated HDL were quantified using western blotting and high-performance liquid chromatography (HPLC). In consequence, incubation with VLDL showed the increase of net amount of apoC-II and apoC-III in the HDL. HPLC analysis revealed that the biotin-labeled apolipoproteins, including apoCs and apolipoprotein E, were preferably transferred to the larger HDL3. No effect of cholesteryl ester transfer protein inhibitor on the apoC transfers was observed. Quantification of apoCs levels in HDL2 and HDL3 from healthy subjects (n = 8) showed large individual differences between apoC-II and apoC-III levels. These results suggest that both apoC-II and apoC-III transfer disproportionately from VLDL to HDL2 and the larger HDL3, and these transfers might be involved in individual triglyceride metabolism.Keywords
Funding Information
- Japan Society for the Promotion of Science (17K15771, 19K07932)
- Hokuto Foundation for Bioscience
This publication has 43 references indexed in Scilit:
- Biochemical characterization of cholesteryl ester transfer protein inhibitorsJournal of Lipid Research, 2010
- Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn StudyClinical Chemistry, 2008
- Apolipoprotein C-III: understanding an emerging cardiovascular risk factorClinical Science, 2008
- Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasmaJournal of Lipid Research, 2006
- Plasma turnover of HDL apoC-I, apoC-III, and apoE in humansJournal of Lipid Research, 2003
- Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsionsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2003
- Structure and Expression of the Mouse Apolipoprotein C2 GeneGenomics, 1993
- Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.JCI Insight, 1986
- Plasma High-Density LipoproteinsThe New England Journal of Medicine, 1978
- Hypertriglyceridemia Associated with Deficiency of Apolipoprotein C-IIThe New England Journal of Medicine, 1978